and preclinical data suggest that menin inhibitors may enhance the efficacy of KIT inhibitors in GIST. We are excited to explore the potential of ziftomenib in combination with imatinib in patients with advanced GIST, with the goal of providing a new treatment option for this patient population.
Despite the financial losses reported for the quarter, we remain confident in the potential of ziftomenib and our broader pipeline of menin inhibitors. With our strong cash reserves and ongoing clinical advancements, we are well-positioned to continue our research and development efforts with a focus on delivering innovative therapies for patients in need. Thank you for your continued support, and we look forward to updating you on our progress in the coming months.”
[End of Transcript]